Comparison of HLA-identical sibling bone marrow transplants (BMT) versus interferon plus cytarabine (IFN/Ara-C) for chronic myelogenous leukemia (CML) in chronic phase (CP).

被引：0
|
作者：
Guilhot, F
Sobocinski, K
Guilhot, J
Zhang, M
Giralt, S
Harousseau, JL
Michallet, M
Maloisel, F
Blaise, D
Guerci, A
Horowitz, M
机构：
[1] CHRU, France Intergrp LMC, Poitiers, France
[2] Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Milwaukee, WI 53226 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2343
引用
收藏
页码：545A / 545A
页数：1
相关论文
共 50 条
  • [31] Interferon alpha (IFN-A) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Kantarjian, H
    OBrien, S
    Beran, M
    Koller, C
    Andreeff, M
    Rios, MB
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1995, 86 (10) : 2105 - 2105
  • [32] Effect of interferon-alpha (IFN-A) therapy on bone marrow (BM) fibrosis in chronic myelogenous leukemia (CML)
    Wilhelm, M
    Ramos, CM
    OBrien, S
    Pierce, S
    Keating, M
    Talpaz, M
    Kantarjian, H
    BLOOD, 1996, 88 (10) : 3537 - 3537
  • [33] Successful Bone Marrow Transplantation in a Pediatric Patient With Chronic Myeloid Leukemia from a HLA-Identical Sibling Selected by Preimplantation HLA Testing
    Goussetis, Evgenios
    Constantoulakis, Pantelis
    Kitra, Vasiliki
    Peristeri, Ioulia
    Mastrominas, Minas
    Baka, Margarita
    Papadimitropoulos, Miltiadis
    Karamolegos, Christos
    Paisiou, Anna
    Vasilatou-Kosmidis, Helen
    Graphakos, Stelios
    PEDIATRIC BLOOD & CANCER, 2011, 57 (02) : 345 - 347
  • [34] HLA-IDENTICAL MARROW TRANSPLANTATION DURING ACCELERATED-PHASE CHRONIC MYELOGENOUS LEUKEMIA - ANALYSIS OF SURVIVAL AND REMISSION DURATION
    MARTIN, PJ
    CLIFT, RA
    FISHER, LD
    BUCKNER, CD
    HANSEN, JA
    APPELBAUM, FR
    DONEY, KC
    SULLIVAN, KM
    WITHERSPOON, RP
    STORB, R
    THOMAS, ED
    BLOOD, 1988, 72 (06) : 1978 - 1984
  • [35] T cell depletion (TCD) plus salvage immunotherapy with donor leukocyte infusions (DLI) as a strategy to reduce regimen-related mortality without compromising survival in chronic phase (CP) chronic myelogenous leukemia (CML) patients undergoing HLA-identical sibling or partially matched family donor marrow transplants.
    Drobyski, WR
    Hessner, M
    Pelz, C
    Kabler-Babbitt, C
    Vesole, DH
    Keever-Taylor, CA
    BLOOD, 1998, 92 (10) : 342B - 342B
  • [36] HLA-IDENTICAL SIBLING DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - INFLUENCE OF GVHD PROPHYLAXIS ON OUTCOME
    MARKS, DI
    HUGHES, TP
    SZYDLO, R
    KELLY, S
    CULLIS, JO
    SCHWARER, AP
    MACKINNON, S
    APPERLEY, J
    BARRETT, AJ
    HOWS, JM
    GOLDMAN, JM
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) : 383 - 390
  • [37] Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia
    R Morariu-Zamfir
    V Rocha
    A Devergie
    G Socié
    P Ribaud
    H Esperou
    N Parquet
    P Guardiola
    L Dal Cortivo
    H Bittencourt
    F Garnier
    R Traineau
    JP Marolleau
    S Chevret
    E Gluckman
    Bone Marrow Transplantation, 2001, 27 : 575 - 580
  • [38] Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia
    Morariu-Zamfir, R
    Rocha, V
    Devergie, A
    Socié, G
    Ribaud, P
    Esperou, H
    Parquet, N
    Guardiola, P
    Dal Cortivo, L
    Bittencourt, H
    Garnier, F
    Traineau, R
    Marolleau, JP
    Chevret, S
    Gluckman, E
    BONE MARROW TRANSPLANTATION, 2001, 27 (06) : 575 - 580
  • [39] A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)
    Kühr, T
    Burgstaller, S
    Apfelbeck, U
    Linkesch, W
    Seewann, H
    Fridrik, M
    Michlmayr, G
    Krieger, O
    Lutz, D
    Lin, W
    Pont, J
    Köck, L
    Abbrederis, K
    Baldinger, C
    Buder, R
    Geissler, D
    Hausmaninger, H
    Lang, A
    Zabernigg, A
    Duba, C
    Hilbe, W
    Eisterer, W
    Fiegl, M
    Greil, R
    Gastl, G
    Thaler, J
    LEUKEMIA RESEARCH, 2003, 27 (05) : 405 - 411
  • [40] Imatinib (I) plus etoposide (Vp16) compared to I plus cytarabine (Ara-C) for the frontline treatment of accelerated phase (AP) chronic myeloid leukemia (CML)
    Cervera, E.
    Vargas, P.
    Cruz, J.
    Enriquez, V.
    Martinez, A.
    Lozano, V.
    Candelaria, M.
    Labardini, J.
    Hurtado, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345